Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
-

-

-
-
-
€21.78
 
WKN: A2PLTL / Symbol: STOK / Name: Stoke Therapeutics / Stock / Biotechnology & Medical Research / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Stoke Therapeutics Inc Stock

We see a rather positive sentiment for Stoke Therapeutics Inc with 13 Buy predictions and 2 Sell predictions.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Stoke Therapeutics Inc stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Stoke Therapeutics Inc in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Stoke Therapeutics Inc vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Stoke Therapeutics Inc - 78.846% 53.719% 32.857% 93.750% -69.000% -
Personalis Inc -0.750% -2.467% -3.170% -44.600% -35.385% -92.851% -
Immuron 5.360% -0.885% 44.516% 30.994% 34.132% -55.200% -

Comments

Prediction Buy
Perf. (%) 39.78%
Target price 15.672
Change
Ends at 26.03.25

Stoke Therapeutics, Inc. (NASDAQ: STOK) had its price target raised by analysts at Wedbush from $13.00 to $17.00. They now have an "outperform" rating on the stock.
Ratings data for STOK provided by MarketBeat
Show more

Stoke Therapeutics, Inc. (NASDAQ: STOK) was upgraded by analysts at TD Cowen from a "market perform" rating to an "outperform" rating.
Ratings data for STOK provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 39.78%
Target price 32.242
Change
Ends at 26.03.25

Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Ratings data for STOK provided by MarketBeat
Show more